Romosozumab for the treatment of osteoporosis
Leonardo Bandeira1, E Michael Lewiecki2, John P Bilezikian1
1a Department of Medicine , College of Physicians and Surgeons, Columbia University Medical Center , New York , NY , USA.
Introduction:
Sclerostin, a glycoprotein produced primarily by osteocytes, blocks the canonical Wnt signaling bone formation pathway. Romosozumab is a humanized monoclonal antibody to sclerostin that binds to sclerostin, permitting the engagement of Wnt ligands with their co-receptors, resulting in an increase in bone formation and bone mineral density (BMD). Clinical studies with romosozumab have shown dramatic improvements in BMD at the spine and hip. Romosozumab is associated with improvement in bone strength through mechanisms that include increases in bone formation and, different from classical osteoanabolic agents, suppression of bone resorption. Areas covered: Herein, the authors highlight the available data on romosozumab for the treatment of osteoporosis. This includes the latest data on the efficacy, pharmacokinetics and pharmacodynamics as well as safety and tolerability data. Expert opinion: Monthly subcutaneous dosing of romosozumab reduces the risk of vertebral and clinical fractures in women with postmenopausal osteoporosis, with a favorable balance of benefits and risks. Romosozumab is a promising emerging anabolic agent with a novel mechanism of action that may expand the options for treating osteoporotic patients at high risk of fracture.
Insights
Romosozumab, an antibody targeting sclerostin, effectively increases bone mineral density and reduces fracture risk in postmenopausal osteoporosis. This novel anabolic agent offers a promising treatment option for high-risk patients.
Area of Science:
- Endocrinology
- Bone Biology
- Pharmacology
Background:
- Sclerostin inhibits bone formation by blocking Wnt signaling.
- Osteoporosis treatment aims to increase bone mineral density (BMD) and reduce fracture risk.
Purpose of the Study:
- To review available data on romosozumab for osteoporosis treatment.
- To highlight efficacy, pharmacokinetics, pharmacodynamics, safety, and tolerability.
Main Methods:
- Review of clinical studies and available data on romosozumab.
- Analysis of its mechanism of action, including Wnt pathway modulation.
Main Results:
- Romosozumab treatment significantly increases BMD at the spine and hip.
- It reduces the risk of vertebral and clinical fractures in postmenopausal women.
- Romosozumab enhances bone formation and suppresses bone resorption.
Conclusions:
- Monthly subcutaneous romosozumab demonstrates a favorable benefit-risk profile for postmenopausal osteoporosis.
- It represents a novel anabolic agent expanding therapeutic options for high-fracture-risk individuals.
More Related Videos
Related Concept Videos
01:31Osteoclasts in Bone Remodeling
01:40Bone Remodeling
01:17Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
01:29Bone Disorders
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:25Role of Vitamins in Maintaining Bone Health
Vitamin A
Vitamin A is involved in the process of bone remodeling. Retinoic acid, the active metabolite of Vitamin A, has nuclear receptors in osteoblasts and osteoclasts, which are involved in bone remodeling.
Vitamin B12
Vitamin B12 acts as a cofactor during the formation of osteoblast-related proteins, such as osteocalcin. Vitamin B12 plays a role...
01:31Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...